Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Yumanity Therapeutics initiated with a Buy at H.C. Wainwright » 06:06
06/04/21
06/04
06:06
06/04/21
06:06
YMTX

Yumanity Therapeutics

$15.12 /

-0.04 (-0.26%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein initiated coverage of Yumanity Therapeutics with a Buy rating and $39 price target. As a clinical-stage biotechnology company focusing on neurodegenerative diseases, Yumanity differs from its competitors, riven by unbiased screens rather than testing a disease-modifying hypothesis in the clinics, Fein tells investors in a research note.

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$15.12 /

-0.04 (-0.26%)

YMTX Yumanity Therapeutics
$15.12 /

-0.04 (-0.26%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$15.12 /

-0.04 (-0.26%)

YMTX Yumanity Therapeutics
$15.12 /

-0.04 (-0.26%)

Conference/Events
Yumanity Therapeutics to host virtual research and development day » 11:25
05/17/21
05/17
11:25
05/17/21
11:25
YMTX

Yumanity Therapeutics

$14.16 /

-0.06 (-0.42%)

Virtual Research and…

Virtual Research and Development day to be held on May 17 at 12 pm. Webcast Link

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$14.16 /

-0.06 (-0.42%)

YMTX Yumanity Therapeutics
$14.16 /

-0.06 (-0.42%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$14.16 /

-0.06 (-0.42%)

YMTX Yumanity Therapeutics
$14.16 /

-0.06 (-0.42%)

Conference/Events
Yumanity Therapeutics to host virtual research and development day » 04:55
05/17/21
05/17
04:55
05/17/21
04:55
YMTX

Yumanity Therapeutics

$14.15 /

-0.15 (-1.05%)

Virtual Research and…

Virtual Research and Development day to be held on May 17 at 12 pm. Webcast Link

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$14.15 /

-0.15 (-1.05%)

YMTX Yumanity Therapeutics
$14.15 /

-0.15 (-1.05%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$14.15 /

-0.15 (-1.05%)

YMTX Yumanity Therapeutics
$14.15 /

-0.15 (-1.05%)

Over a month ago
Conference/Events
Yumanity Therapeutics to host virtual research and development day » 15:10
05/13/21
05/13
15:10
05/13/21
15:10
YMTX

Yumanity Therapeutics

$14.49 /

-0.4 (-2.69%)

Virtual Research and…

Virtual Research and Development day to be held on May 17 at 12 pm. Webcast Link

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$14.49 /

-0.4 (-2.69%)

YMTX Yumanity Therapeutics
$14.49 /

-0.4 (-2.69%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$14.49 /

-0.4 (-2.69%)

YMTX Yumanity Therapeutics
$14.49 /

-0.4 (-2.69%)

Hot Stocks
Yumanity Therapeutics expects cash to fund operations into 3Q22 » 07:48
05/13/21
05/13
07:48
05/13/21
07:48
YMTX

Yumanity Therapeutics

$14.89 /

-0.11 (-0.73%)

Cash position: As of…

Cash position: As of March 31, 2021, cash, cash equivalents and investments was $62.9 million, compared to $85.3 million as of December 31, 2021. The decrease was primarily due to spending on the clinical development of YMTX-7739 and costs related to being a public company, as well as certain one-time costs related to the Company's reverse merger with Proteostasis Therapeutics. The Company believes its cash, cash equivalents and marketable securities are sufficient to fund operations into the third quarter of 2022.

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

Hot Stocks
Yumanity Therapeutics announces anticipated upcoming milestones » 07:48
05/13/21
05/13
07:48
05/13/21
07:48
YMTX

Yumanity Therapeutics

$14.89 /

-0.11 (-0.73%)

The Company remains on…

The Company remains on track to announce preliminary results from the Phase 1b part of the MAD study of YTX-7739 in patients with Parkinson's disease by mid-year 2021. The Company anticipates initiating a Phase 1 trial of YTX-9184, a novel SCD inhibitor being developed for the treatment of dementia with Lewy Bodies, in the second half of 2021. Yumanity is hosting a virtual R&D Day on May 17, 2021 at 12:00 p.m. EDT. The event is available via webcast at URL Following the conclusion of the live event, a replay will be available for 60 days on the Events & Presentations page of the Yumanity website.

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

Earnings
Yumanity Therapeutics reports Q1 EPS (85c), two est. (83c) » 07:47
05/13/21
05/13
07:47
05/13/21
07:47
YMTX

Yumanity Therapeutics

$14.89 /

-0.11 (-0.73%)

Reports Q1 revenue…

Reports Q1 revenue $3.53M, two est. $500,000. "The first quarter of 2021 was Yumanity's first as a public company and we made continued progress advancing our lead program, YTX-7739, in clinical development for Parkinson's disease," said Richard Peters, M.D., Ph.D., President, Chief Executive Officer and Director of Yumanity. "Notably, we recently reported topline results from our Phase 1a multiple-ascending dose healthy volunteers study of YTX-7739, which demonstrated its ability to engage a novel biological target that, when engaged at similar levels in an animal model of Parkinson's disease, improved motor function. We look forward to continued progress throughout the year, including reporting preliminary results from the Phase 1b portion of the MAD study in patients with Parkinson's disease and introducing a second program into clinical development later this year. We will be hosting our first R&D Day on May 17, 2021 when we will further detail the results of our Phase 1 trial of YTX-7739 in healthy subjects."

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

YMTX Yumanity Therapeutics
$14.89 /

-0.11 (-0.73%)

Conference/Events
Yumanity Therapeutics management to meet virtually with Jefferies » 04:55
05/03/21
05/03
04:55
05/03/21
04:55
YMTX

Yumanity Therapeutics

$16.86 /

-0.04 (-0.24%)

Virtual Meeting to be…

Virtual Meeting to be held on May 3 hosted by Jefferies.

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$16.86 /

-0.04 (-0.24%)

YMTX Yumanity Therapeutics
$16.86 /

-0.04 (-0.24%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$16.86 /

-0.04 (-0.24%)

YMTX Yumanity Therapeutics
$16.86 /

-0.04 (-0.24%)

Conference/Events
Yumanity Therapeutics management to meet virtually with Jefferies » 16:11
04/30/21
04/30
16:11
04/30/21
16:11
YMTX

Yumanity Therapeutics

$16.73 /

-0.17 (-1.01%)

Virtual Meeting to be…

Virtual Meeting to be held on May 3 hosted by Jefferies.

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$16.73 /

-0.17 (-1.01%)

YMTX Yumanity Therapeutics
$16.73 /

-0.17 (-1.01%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$16.73 /

-0.17 (-1.01%)

YMTX Yumanity Therapeutics
$16.73 /

-0.17 (-1.01%)

Hot Stocks
Yumanity Therapeutics announces data from Phase 1a MAD study of YTX-7739 » 07:18
04/22/21
04/22
07:18
04/22/21
07:18
YMTX

Yumanity Therapeutics

$17.18 /

-0.18 (-1.04%)

Yumanity Therapeutics…

Yumanity Therapeutics reported that its lead product candidate, YTX-7739, in development for the treatment of Parkinson's disease, demonstrated dose-dependent decreases in target fatty acids, which can be interpreted as evidence of in vivo target engagement, in a Phase 1a multiple ascending dose clinical trial in healthy volunteers. Inhibition of stearoyl-CoA desaturase has been shown to improve motor function and other disease markers in transgenic mouse models of PD. YTX-7739 was also observed to be generally well tolerated in the Phase 1a study. YTX-7739 was discovered through Yumanity's target discovery and drug development platform that is designed to identify disease-modifying therapeutics against newly identified targets for neurodegenerative diseases. Preclinical work has shown that SCD inhibition by YTX-7739, an orally available, brain penetrant small molecule, can overcome the toxicity of pathogenic alpha-synuclein, a known risk factor for PD, both in vitro and in animal models. Further, the fatty acid desaturation index which measures the ratio of SCD's product to its substrate has demonstrated utility as a biomarker to gauge SCD inhibition in animals treated with YTX-7739. This part of the Phase 1, placebo-controlled, randomized, double-blind study, investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of once daily oral administration of two doses of YTX-7739 for 14 to 28 days in 16 healthy male and female volunteers. The study included two cohorts of eight subjects each, randomized to treatment or placebo in a 6:2 ratio. YTX-7739 was observed to be generally well tolerated in this part of the study. There were no serious adverse events and all treatment emergent adverse events were either mild or moderate in severity. Plasma pharmacokinetics support once daily dosing, and relevant drug concentrations were measured in the cerebrospinal fluid. Target engagement was achieved, as evidenced by dose dependent decreases in the plasma FA-DI, within the range associated with restoration of motor function in animal models of Parkinson's disease.

ShowHide Related Items >><<
YMTX Yumanity Therapeutics
$17.18 /

-0.18 (-1.04%)

YMTX Yumanity Therapeutics
$17.18 /

-0.18 (-1.04%)

04/01/21 Jefferies
Yumanity Therapeutics initiated with a Buy at Jefferies
01/05/21 Piper Sandler
Piper wants to own Yumanity with shares turning corner post merger
12/23/20 Piper Sandler
Piper updates Yumanity Therapeutics price target to $36 after merger completion
YMTX Yumanity Therapeutics
$17.18 /

-0.18 (-1.04%)

YMTX Yumanity Therapeutics
$17.18 /

-0.18 (-1.04%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.